Aldeyra Therapeutics (ALDX) to Release Earnings on Wednesday

Key Points

• Q1 2026 earnings are due after the market close on May 13, 2026, with analysts forecasting EPS of ($0.13) and a conference call set for May 15 at 4:00 PM ET.
• Director Richard Douglas bought 70,000 shares at about $1.40 on March 19, raising his stake to 195,000 shares; corporate insiders hold roughly 8.5% of the company.
• Shares opened at $1.72 and sit in a 12‑month range of $1.07–$6.18 with a market cap of about $103.8M, while analysts' consensus is a "Hold" with an average target price of $5.50 (1 Buy, 2 Hold, 1 Sell).

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) is expected to release its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect Aldeyra Therapeutics to post earnings of ($0.13) per share for the quarter. Parties can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last issued its earnings results on Friday, February 27th. The biotechnology company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.03. On average, analysts expect Aldeyra Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Aldeyra Therapeutics Trading Up 6.2%

Shares of Aldeyra Therapeutics stock opened at $1.72 on Wednesday. The company has a fifty day moving average price of $2.75 and a 200 day moving average price of $4.23. Aldeyra Therapeutics has a twelve month low of $1.07 and a twelve month high of $6.18. The stock has a market cap of $103.75 million, a price-to-earnings ratio of -3.02 and a beta of 1.16.

Insider Buying and Selling at Aldeyra Therapeutics

In other Aldeyra Therapeutics news, Director Richard Douglas bought 70,000 shares of the company's stock in a transaction dated Thursday, March 19th. The shares were acquired at an average cost of $1.40 per share, with a total value of $98,000.00. Following the completion of the transaction, the director owned 195,000 shares in the company, valued at $273,000. The trade was a 56.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Aldeyra Therapeutics

Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in Aldeyra Therapeutics by 2.6% during the 3rd quarter. Vanguard Group Inc. now owns 3,591,869 shares of the biotechnology company's stock worth $18,750,000 after purchasing an additional 90,276 shares during the last quarter. AQR Capital Management LLC grew its stake in Aldeyra Therapeutics by 275.4% in the second quarter. AQR Capital Management LLC now owns 1,473,812 shares of the biotechnology company's stock worth $5,645,000 after purchasing an additional 1,081,257 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Aldeyra Therapeutics by 0.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,146,597 shares of the biotechnology company's stock valued at $4,392,000 after acquiring an additional 8,769 shares in the last quarter. Kennedy Capital Management LLC boosted its holdings in shares of Aldeyra Therapeutics by 61.9% in the 3rd quarter. Kennedy Capital Management LLC now owns 1,112,213 shares of the biotechnology company's stock valued at $5,806,000 after buying an additional 425,245 shares during the period. Finally, Jacobs Levy Equity Management Inc. boosted its stake in Aldeyra Therapeutics by 2.2% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 968,751 shares of the biotechnology company's stock valued at $5,018,000 after acquiring an additional 21,200 shares during the period. Institutional investors and hedge funds own 59.71% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have commented on ALDX shares. Wall Street Zen upgraded Aldeyra Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, April 18th. BTIG Research reiterated a "buy" rating on shares of Aldeyra Therapeutics in a report on Tuesday, March 17th. Finally, HC Wainwright reissued a "neutral" rating and set a $2.00 price target (down from $10.00) on shares of Aldeyra Therapeutics in a research report on Wednesday, March 18th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $5.50.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company's research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company's lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.